A Chinese drugmaker has secured 100 million doses of the coronavirus vaccine co-developed by Pfizer Inc. and Germany's BioNTech SE, as the country seeks overseas shots in addition to home-made ones. The German vaccine maker will supply no fewer than 100 million doses for China by the end of 2021, Fosun said in a statement filed with the Hong Kong Stock Exchange Wednesday. The mainland company has been authorized by BioNTech to exclusively develop and commercialize its vaccines in mainland China, Hong Kong and Macau. Earlier, the Food and Health Bureau announced an agreement with Fosun Pharma to secure a maximum of 7.5 million doses. The vaccines for Hong Kong will be produced in Europe.

Source: The Standard December 16, 2020 05:15 UTC